Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 23, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 600,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,477.8865 pence per share.
- Treasury Shares Held: 288,942,678 shares following the transaction.
- Shares in Issue: 5,728,746,303 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 17, 2006. The total number of shares held in Treasury increased to 288,942,678.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,728,746,303) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count of 288,942,678.
- Note that this filing is a notification of a specific transaction and does not include periodic financial performance data.